bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S2 from Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Authors: Le Dung T. , Picozzi Vincent J. , Ko Andrew H. , Wainberg Zev A. , Kindler Hedy , Wang-Gillam Andrea , Oberstein Paul , Morse Michael A. , Zeh Herbert J. , Weekes Colin , Reid Tony , Borazanci Erkut , Crocenzi Todd , LoConte Noelle K. , Musher Benjamin , Laheru Dan , Murphy Aimee , Whiting Chan , Nair Nitya , Enstrom Amanda , Ferber Sandy , Brockstedt Dirk G. , Jaffee Elizabeth M.
Published: April 2023

Chemotherapy regimens in Arm C
Figure S4 from POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Authors: Baird Richard D. , van Rossum Annelot G.J. , Oliveira Mafalda , Beelen Karin , Gao Meiling , Schrier Mariette , Mandjes Ingrid A.M. , Garcia-Corbacho Javier , Vallier Anne-Laure , Dougall Greig , van Werkhoven Erik , Linossi Constanza , Kumar Sanjeev , van Tinteren Harm , Callari Maurizio , Beddowes Emma , Perez-Garcia José-Manuel , Rosing Hilde , Platte Else , Nederlof Petra , Schot Margaret , de Vries Schultink Aurelia , Bernards René , Saura Cristina , Gallagher William , Cortès Javier , Caldas Carlos , Linn Sabine C.
Published: April 2023

PIK3CA mutations detected at baseline (in samples from 8 out of 30 patients)
Table S6 from Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer
Authors: Goldstein Jennifer B. , Zhao Li , Wang Xuemei , Ghelman Yael , Overman Michael J. , Javle Milind M. , Shroff Rachna T. , Varadhachary Gauri R. , Wolff Robert A. , McAllister Florencia , Futreal Andrew , Fogelman David R.
Published: April 2023

Univariate logistic regression models for deleterious mutation among 133 sequenced subjects (n = 26 with deleterious mutation).
Supplementary Material & Methods from AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
Authors: Cidado Justin , Boiko Scott , Proia Theresa , Ferguson Douglas , Criscione Steven W. , San Martin Maryann , Pop-Damkov Petar , Su Nancy , Roamio Franklin Valar Nila , Sekhar Reddy Chilamakuri Chandra , D'Santos Clive S. , Shao Wenlin , Saeh Jamal C. , Koch Raphael , Weinstock David M. , Zinda Michael , Fawell Stephen E. , Drew Lisa
Published: April 2023

Material, methods, supplementary references, and list of supplementary tables.
Table S2 from Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer
Authors: Goldstein Jennifer B. , Zhao Li , Wang Xuemei , Ghelman Yael , Overman Michael J. , Javle Milind M. , Shroff Rachna T. , Varadhachary Gauri R. , Wolff Robert A. , McAllister Florencia , Futreal Andrew , Fogelman David R.
Published: April 2023

Variants of Unknown Significance Identified in Study Cohort
Table S1 from Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer
Authors: Goldstein Jennifer B. , Zhao Li , Wang Xuemei , Ghelman Yael , Overman Michael J. , Javle Milind M. , Shroff Rachna T. , Varadhachary Gauri R. , Wolff Robert A. , McAllister Florencia , Futreal Andrew , Fogelman David R.
Published: April 2023

Patient characteristics with statistical comparison between sequenced and unsequenced cohorts among 233 patients.
Supplemental Table Legend from Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer
Authors: Goldstein Jennifer B. , Zhao Li , Wang Xuemei , Ghelman Yael , Overman Michael J. , Javle Milind M. , Shroff Rachna T. , Varadhachary Gauri R. , Wolff Robert A. , McAllister Florencia , Futreal Andrew , Fogelman David R.
Published: April 2023

Supplemental Table Legend
Supplementary Figure S3 from AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
Authors: Cidado Justin , Boiko Scott , Proia Theresa , Ferguson Douglas , Criscione Steven W. , San Martin Maryann , Pop-Damkov Petar , Su Nancy , Roamio Franklin Valar Nila , Sekhar Reddy Chilamakuri Chandra , D'Santos Clive S. , Shao Wenlin , Saeh Jamal C. , Koch Raphael , Weinstock David M. , Zinda Michael , Fawell Stephen E. , Drew Lisa
Published: April 2023

AZD4573 induces rapid cell death across a diverse panel of hematological cancer cell lines.
Supplementary Data from Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer
Authors: Glumac Paige M. , Gallant Joseph P. , Shapovalova Mariya , Li Yingming , Murugan Paari , Gupta Shilpa , Coleman Ilsa M. , Nelson Peter S. , Dehm Scott M. , LeBeau Aaron M.
Published: April 2023

Figure S1. CD133 expression correlated with PSA expression. Figure S2. CD133 expression in xenografts. Figure S3. Characterization of labeled HA10. Table S1. Ex vivo biodistribution data.
Supplementary Figure S2 from AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
Authors: Cidado Justin , Boiko Scott , Proia Theresa , Ferguson Douglas , Criscione Steven W. , San Martin Maryann , Pop-Damkov Petar , Su Nancy , Roamio Franklin Valar Nila , Sekhar Reddy Chilamakuri Chandra , D'Santos Clive S. , Shao Wenlin , Saeh Jamal C. , Koch Raphael , Weinstock David M. , Zinda Michael , Fawell Stephen E. , Drew Lisa
Published: April 2023

Transient exposure to AZD4573 induces apoptosis upon depletion of Mcl-1.
Supplementary Figure S1 from AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells
Authors: Cidado Justin , Boiko Scott , Proia Theresa , Ferguson Douglas , Criscione Steven W. , San Martin Maryann , Pop-Damkov Petar , Su Nancy , Roamio Franklin Valar Nila , Sekhar Reddy Chilamakuri Chandra , D'Santos Clive S. , Shao Wenlin , Saeh Jamal C. , Koch Raphael , Weinstock David M. , Zinda Michael , Fawell Stephen E. , Drew Lisa
Published: April 2023

Identification of highly selective and potent CDK9 inhibitor, AZD4573.
Supplementary Data from Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Authors: Falchook Gerald , Rosen Seth , LoRusso Patricia , Watts Justin , Gupta Shilpa , Coombs Catherine C. , Talpaz Moshe , Kurzrock Razelle , Mita Monica , Cassaday Ryan , Harb Wael , Peguero Julio , Smith David C. , Piha-Paul Sarina A. , Szmulewitz Russ , Noel Marcus S. , Yeleswaram Swamy , Liu Phillip , Switzky Julie , Zhou Gongfu , Zheng Fred , Mehta Amitkumar
Published: April 2023

Falchook et al: Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies - Supplemental Methods, Results, Tables, and Figures
Supplement from Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging
Authors: Bowen Stephen R. , Hippe Daniel S. , Chaovalitwongse W. Art , Duan Chunyan , Thammasorn Phawis , Liu Xiao , Miyaoka Robert S. , Vesselle Hubert J. , Kinahan Paul E. , Rengan Ramesh , Zeng Jing
Published: April 2023

Complete methodological description of the Voxel Forecast modeling framework and benchmarking simulations.
Supplementary Table S1 from A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Authors: Nowicki Theodore S. , Berent-Maoz Beata , Cheung-Lau Gardenia , Huang Rong Rong , Wang Xiaoyan , Tsoi Jennifer , Kaplan-Lefko Paula , Cabrera Paula , Tran Justin , Pang Jia , Macabali Mignonette , Garcilazo Ivan Perez , Carretero Ignacio Baselga , Kalbasi Anusha , Cochran Alistair J. , Grasso Catherine S. , Hu-Lieskovan Siwen , Chmielowski Bartosz , Comin-Anduix Begoña , Singh Arun , Ribas Antoni
Published: April 2023

List of mass cytometry antibodies utilized.
Supplemental Figure Legends from A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Authors: Nowicki Theodore S. , Berent-Maoz Beata , Cheung-Lau Gardenia , Huang Rong Rong , Wang Xiaoyan , Tsoi Jennifer , Kaplan-Lefko Paula , Cabrera Paula , Tran Justin , Pang Jia , Macabali Mignonette , Garcilazo Ivan Perez , Carretero Ignacio Baselga , Kalbasi Anusha , Cochran Alistair J. , Grasso Catherine S. , Hu-Lieskovan Siwen , Chmielowski Bartosz , Comin-Anduix Begoña , Singh Arun , Ribas Antoni
Published: April 2023

Supplemental Figure legends for Figures S1-S5
Supplementary Data from Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death
Authors: Kulkarni Prathamesh M. , Robinson Eric J. , Sarin Pradhan Jaya , Gartrell-Corrado Robyn D. , Rohr Bethany R. , Trager Megan H. , Geskin Larisa J. , Kluger Harriet M. , Wong Pok Fai , Acs Balazs , Rizk Emanuelle M. , Yang Chen , Mondal Manas , Moore Michael R. , Osman Iman , Phelps Robert , Horst Basil A. , Chen Zhe S. , Ferringer Tammie , Rimm David L. , Wang Jing , Saenger Yvonne M.
Published: April 2023

Supplementary Data from Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death
Table S4 from Functional Genomics Identifies Hepatitis-Induced STAT3–TYRO3–STAT3 Signaling as a Potential Therapeutic Target of Hepatoma
Authors: Tsai Chia-Liang , Chang Jeng-Shou , Yu Ming-Chin , Lee Chern-Horng , Chen Tse-Ching , Chuang Wen-Yu , Kuo Wei-Liang , Lin Chen-Chun , Lin Shi-Ming , Hsieh Sen-Yung
Published: April 2023

Correlation between TYRO3 level and clinicopathologic features in 120 HCC patients
Suppl Fig 7 from Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
Authors: Berberich Anne , Kessler Tobias , Thomé Carina M. , Pusch Stefan , Hielscher Thomas , Sahm Felix , Oezen Iris , Schmitt Lara-Marie , Ciprut Sara , Hucke Nanina , Ruebmann Petra , Fischer Manuel , Lemke Dieter , Breckwoldt Michael O. , von Deimling Andreas , Bendszus Martin , Platten Michael , Wick Wolfgang
Published: April 2023

IGFBP1 mRNA expression after treatment with trametinib or IGFBP1 knockdown.
Supplementary Data from Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission
Authors: Lv Meng , Wang Yu , Chang Ying-Jun , Zhang Xiao-Hui , Xu Lan-Ping , Jiang Qian , Jiang Hao , Lu Jin , Chen Huan , Han Wei , Wang Feng-Rong , Wang Jing-Zhi , Chen Yao , Yan Chen-Hua , Zhang Yuan-Yuan , Sun Yu-Qian , Mo Xiao-Dong , Zhu Hong-Hu , Jia Jin-Song , Zhao Ting , Wang Jing , Liu Kai-Yan , Huang Xiao-Jun
Published: April 2023

Figure S1-S3. Table S1-S3
Suppl Fig 5 from Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
Authors: Berberich Anne , Kessler Tobias , Thomé Carina M. , Pusch Stefan , Hielscher Thomas , Sahm Felix , Oezen Iris , Schmitt Lara-Marie , Ciprut Sara , Hucke Nanina , Ruebmann Petra , Fischer Manuel , Lemke Dieter , Breckwoldt Michael O. , von Deimling Andreas , Bendszus Martin , Platten Michael , Wick Wolfgang
Published: April 2023

In vivo toxicity and on-target efficacy. â€¨
Suppl Fig 4 from Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
Authors: Berberich Anne , Kessler Tobias , Thomé Carina M. , Pusch Stefan , Hielscher Thomas , Sahm Felix , Oezen Iris , Schmitt Lara-Marie , Ciprut Sara , Hucke Nanina , Ruebmann Petra , Fischer Manuel , Lemke Dieter , Breckwoldt Michael O. , von Deimling Andreas , Bendszus Martin , Platten Michael , Wick Wolfgang
Published: April 2023

Synergistic effects of trametinib and RG7388 treatment.
Suppl Fig 1 from Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib
Authors: Berberich Anne , Kessler Tobias , Thomé Carina M. , Pusch Stefan , Hielscher Thomas , Sahm Felix , Oezen Iris , Schmitt Lara-Marie , Ciprut Sara , Hucke Nanina , Ruebmann Petra , Fischer Manuel , Lemke Dieter , Breckwoldt Michael O. , von Deimling Andreas , Bendszus Martin , Platten Michael , Wick Wolfgang
Published: April 2023

Effects of short-term RG7388 treatment in glioblastoma cell lines.
Supplementary Figure 4 from Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Authors: Pearson Alex , Proszek Paula , Pascual Javier , Fribbens Charlotte , Shamsher Monee K. , Kingston Belinda , O'Leary Ben , Herrera-Abreu Maria T. , Cutts Rosalind J. , Garcia-Murillas Isaac , Bye Hannah , Walker Brian A. , Gonzalez De Castro David , Yuan Lina , Jamal Sabri , Hubank Mike , Lopez-Knowles Elena , Schuster Eugene F. , Dowsett Mitch , Osin Peter , Nerurkar Ashutosh , Parton Marina , Okines Alicia F.C. , Johnston Stephen R.D. , Ring Alistair , Turner Nicholas C.
Published: April 2023

NCOR expression following NF1 loss
Supplementary Figure 2 from Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
Authors: Pearson Alex , Proszek Paula , Pascual Javier , Fribbens Charlotte , Shamsher Monee K. , Kingston Belinda , O'Leary Ben , Herrera-Abreu Maria T. , Cutts Rosalind J. , Garcia-Murillas Isaac , Bye Hannah , Walker Brian A. , Gonzalez De Castro David , Yuan Lina , Jamal Sabri , Hubank Mike , Lopez-Knowles Elena , Schuster Eugene F. , Dowsett Mitch , Osin Peter , Nerurkar Ashutosh , Parton Marina , Okines Alicia F.C. , Johnston Stephen R.D. , Ring Alistair , Turner Nicholas C.
Published: April 2023

Genetic profile of ER positive primary breast cancers that 'switch' to triple negative recurrent advanced breast cancer
Figure S2 from Elastography Can Map the Local Inverse Relationship between Shear Modulus and Drug Delivery within the Pancreatic Ductal Adenocarcinoma Microenvironment
Authors: Wang Hexuan , Mislati Reem , Ahmed Rifat , Vincent Phuong , Nwabunwanne Solumtochukwu F. , Gunn Jason R. , Pogue Brian W. , Doyley Marvin M.
Published: April 2023

Montage of shear modulus elastograms obtained from (a) AsPC-1 and (b) BxPC-3 tumors. We acquired these images 2mm slice interval. The dotted lines denote the tumor in each scan plane. White stars indicated the scan plane along which the tumors were cut and stained for Masson's Trichrome (c, f), lectin (d, g) and Verteporfin uptake (e, h).
Figure S1 from Elastography Can Map the Local Inverse Relationship between Shear Modulus and Drug Delivery within the Pancreatic Ductal Adenocarcinoma Microenvironment
Authors: Wang Hexuan , Mislati Reem , Ahmed Rifat , Vincent Phuong , Nwabunwanne Solumtochukwu F. , Gunn Jason R. , Pogue Brian W. , Doyley Marvin M.
Published: April 2023

Shear wave elasticity imaging experimental setup used to measure the shear modulus of AsPC-1 and BxPC-3 tumor. (a) shows the Verasonics ultrasound scanner used for shear wave imaging equipped with an L-7 probe attached, positioned on top of a gelatin encapsulated tumor as shown in (b). Scan plane, indicated with dotted lines, form which shear wave images were acquired in (c). Serial sections of tumor slices were cut along the ultrasound scan plane. (d) representative sonogram (e) shear modulus elastogram.
Figure S2 from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Authors: Bahleda Rastislav , Italiano Antoine , Hierro Cinta , Mita Alain , Cervantes Andres , Chan Nancy , Awad Mark , Calvo Emiliano , Moreno Victor , Govindan Ramaswamy , Spira Alexander , Gonzalez Martha , Zhong Bob , Santiago-Walker Ademi , Poggesi Italo , Parekh Trilok , Xie Hong , Infante Jeffrey , Tabernero Josep
Published: April 2023

Supplementary Figure S2. Model-predicted and observed serum phosphate concentrations vs erdafitinib plasma concentrations (left panel: total erdafitinib concentrations; right panel: unbound erdafitinib concentrations). Continuous and dashed lines: median and 5th and 95th percentiles of model-based simulations (n=500). Closed symbols: individual observations.
Supplementary Figure S7 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer
Authors: Cao Qi , Song Zhengshuai , Ruan Hailong , Wang Cheng , Yang Xiong , Bao Lin , Wang Keshan , Cheng Gong , Xu TianBo , Xiao Wen , Xiong Zhiyong , Liu Di , Yang Ming , Zhou Diwei , Yang Hongmei , Chen Ke , Zhang Xiaoping
Published: April 2023

A, IHC detection of the expression of PSA in each group was performed. B, Quantified immunohistochemistry for PSA in each group. The results are shown as the mean {plus minus} SD. *p < 0.05; **p < 0.01, ***p < 0.001.
Figure S1A from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors
Authors: Bahleda Rastislav , Italiano Antoine , Hierro Cinta , Mita Alain , Cervantes Andres , Chan Nancy , Awad Mark , Calvo Emiliano , Moreno Victor , Govindan Ramaswamy , Spira Alexander , Gonzalez Martha , Zhong Bob , Santiago-Walker Ademi , Poggesi Italo , Parekh Trilok , Xie Hong , Infante Jeffrey , Tabernero Josep
Published: April 2023

Supplementary Figure S1. Mean concentration-time erdafitinib profiles after a single dose (cycle 1 day 1 [C1D1]) and at steady-state (cycle 2 day 1 [C2D1]) after daily dosing (Panel A) or intermittent dosing (Panel B). 9 mg QD Part 1 at Cycle 2 Day 1 (C2D1) was not reported as n=1.
Supplementary Figure S5 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer
Authors: Cao Qi , Song Zhengshuai , Ruan Hailong , Wang Cheng , Yang Xiong , Bao Lin , Wang Keshan , Cheng Gong , Xu TianBo , Xiao Wen , Xiong Zhiyong , Liu Di , Yang Ming , Zhou Diwei , Yang Hongmei , Chen Ke , Zhang Xiaoping
Published: April 2023

A, 293T cells were co-transfected with HA-AR-V7 with or without Flag-KIF4A, shCHIP, and MYC-Ub for 2 days, and total cell lysates were immunoprecipitated with HA antibody and blotted with the indicated antibodies. B, 293T cells were co-transfected with eGFP-AR with or without Flag-KIF4A, shCHIP, and MYC-Ub for 2 days, and total cell lysates were immunoprecipitated with eGFP antibody and blotted with the indicated antibodies.
Supplementary Figure S1 from Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer
Authors: Cao Qi , Song Zhengshuai , Ruan Hailong , Wang Cheng , Yang Xiong , Bao Lin , Wang Keshan , Cheng Gong , Xu TianBo , Xiao Wen , Xiong Zhiyong , Liu Di , Yang Ming , Zhou Diwei , Yang Hongmei , Chen Ke , Zhang Xiaoping
Published: April 2023

Expression of KIF4A is upregulated and associated with various clinicopathological factors in prostate cancer. A, The BIRC5/AR and ATP8A2/AR correlations were determined by Spearman rank correlation in four prostate cancer datasets. B, The IRS score of the KIF4A expression level in prostate cancer tissues and adjacent normal tissues. C, The IRS score of the KIF4A expression level for each clinical stage of prostate cancer. D, The IRS score of KIF4A expression level for different PSA levels in prostate cancer patients. The results are shown as the mean {plus minus} SD. *p < 0.05; **p < 0.01, ***p < 0.001.
Supplementary Tables from Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study
Authors: Smith Jenny L. , Ries Rhonda E. , Hylkema Tiffany , Alonzo Todd A. , Gerbing Robert B. , Santaguida Marianne T. , Eidenschink Brodersen Lisa , Pardo Laura , Cummings Carrie L. , Loeb Keith R. , Le Quy , Imren Suzan , Leonti Amanda R. , Gamis Alan S. , Aplenc Richard , Kolb E. Anders , Farrar Jason E. , Triche Timothy J. , Nguyen Cu , Meerzaman Daoud , Loken Michael R. , Oehler Vivian G. , Bolouri Hamid , Meshinchi Soheil
Published: April 2023

Supplemental tables including clinical characteristics and differentially expressed gene lists.
Supplementary Figures from Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study
Authors: Smith Jenny L. , Ries Rhonda E. , Hylkema Tiffany , Alonzo Todd A. , Gerbing Robert B. , Santaguida Marianne T. , Eidenschink Brodersen Lisa , Pardo Laura , Cummings Carrie L. , Loeb Keith R. , Le Quy , Imren Suzan , Leonti Amanda R. , Gamis Alan S. , Aplenc Richard , Kolb E. Anders , Farrar Jason E. , Triche Timothy J. , Nguyen Cu , Meerzaman Daoud , Loken Michael R. , Oehler Vivian G. , Bolouri Hamid , Meshinchi Soheil
Published: April 2023

Supplemental Figures including additional Kaplan-Meier plots, heatmaps of surface antigen expression and gene expression, and miRNA correlations.
Table S7 from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Authors: Vaubel Rachael A. , Tian Shulan , Remonde Dioval , Schroeder Mark A. , Mladek Ann C. , Kitange Gaspar J. , Caron Alissa , Kollmeyer Thomas M. , Grove Rebecca , Peng Sen , Carlson Brett L. , Ma Daniel J. , Sarkar Gobinda , Evers Lisa , Decker Paul A. , Yan Huihuang , Dhruv Harshil D. , Berens Michael E. , Wang Qianghu , Marin Bianca M. , Klee Eric W. , Califano Andrea , LaChance Daniel H. , Eckel-Passow Jeanette E. , Verhaak Roel G. , Sulman Erik P. , Burns Terry C. , Meyer Fredrick B. , O'Neill Brian P. , Tran Nhan L. , Giannini Caterina , Jenkins Robert B. , Parney Ian F. , Sarkaria Jann N.
Published: April 2023

PDX Response to Standard Therapy
Supplementary Data from Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites
Authors: Nassar Amin H. , Umeton Renato , Kim Jaegil , Lundgren Kevin , Harshman Lauren , Van Allen Eliezer M. , Preston Mark , Dong Fei , Bellmunt Joaquim , Mouw Kent W. , Choueiri Toni K. , Sonpavde Guru , Kwiatkowski David J.
Published: April 2023

Association of ERCC2 mutation signature counts with ERCC2 alterations across UC subtypes. P values were calculated by two-sided Wilcoxon rank sum test (p<0.05).
Table S4 from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Authors: Vaubel Rachael A. , Tian Shulan , Remonde Dioval , Schroeder Mark A. , Mladek Ann C. , Kitange Gaspar J. , Caron Alissa , Kollmeyer Thomas M. , Grove Rebecca , Peng Sen , Carlson Brett L. , Ma Daniel J. , Sarkar Gobinda , Evers Lisa , Decker Paul A. , Yan Huihuang , Dhruv Harshil D. , Berens Michael E. , Wang Qianghu , Marin Bianca M. , Klee Eric W. , Califano Andrea , LaChance Daniel H. , Eckel-Passow Jeanette E. , Verhaak Roel G. , Sulman Erik P. , Burns Terry C. , Meyer Fredrick B. , O'Neill Brian P. , Tran Nhan L. , Giannini Caterina , Jenkins Robert B. , Parney Ian F. , Sarkaria Jann N.
Published: April 2023

Frequency of genomic alterations in PDX compared to TCGA
Supplementary Data from Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites
Authors: Nassar Amin H. , Umeton Renato , Kim Jaegil , Lundgren Kevin , Harshman Lauren , Van Allen Eliezer M. , Preston Mark , Dong Fei , Bellmunt Joaquim , Mouw Kent W. , Choueiri Toni K. , Sonpavde Guru , Kwiatkowski David J.
Published: April 2023

Histogram showing the distribution of alterations in KDM6A in males and females for 4 subtypes of urothelial carcinoma. Red bars are scaled to show the frequency (%) of female samples with an alteration in KDM6A; Gray bars are scaled to show the frequency of bi-allelic mutation in KDM6A in female samples; and blue bars show the frequency of KDM6A mutation in males. The numbers above each bar indicate the number of samples with each category of alteration; the numbers below show the total number of samples for each sex and UC subtype.
Table S3 from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Authors: Vaubel Rachael A. , Tian Shulan , Remonde Dioval , Schroeder Mark A. , Mladek Ann C. , Kitange Gaspar J. , Caron Alissa , Kollmeyer Thomas M. , Grove Rebecca , Peng Sen , Carlson Brett L. , Ma Daniel J. , Sarkar Gobinda , Evers Lisa , Decker Paul A. , Yan Huihuang , Dhruv Harshil D. , Berens Michael E. , Wang Qianghu , Marin Bianca M. , Klee Eric W. , Califano Andrea , LaChance Daniel H. , Eckel-Passow Jeanette E. , Verhaak Roel G. , Sulman Erik P. , Burns Terry C. , Meyer Fredrick B. , O'Neill Brian P. , Tran Nhan L. , Giannini Caterina , Jenkins Robert B. , Parney Ian F. , Sarkaria Jann N.
Published: April 2023

Short tandem repeat genotype and PDX growth characteristics
Table S1 from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Authors: Vaubel Rachael A. , Tian Shulan , Remonde Dioval , Schroeder Mark A. , Mladek Ann C. , Kitange Gaspar J. , Caron Alissa , Kollmeyer Thomas M. , Grove Rebecca , Peng Sen , Carlson Brett L. , Ma Daniel J. , Sarkar Gobinda , Evers Lisa , Decker Paul A. , Yan Huihuang , Dhruv Harshil D. , Berens Michael E. , Wang Qianghu , Marin Bianca M. , Klee Eric W. , Califano Andrea , LaChance Daniel H. , Eckel-Passow Jeanette E. , Verhaak Roel G. , Sulman Erik P. , Burns Terry C. , Meyer Fredrick B. , O'Neill Brian P. , Tran Nhan L. , Giannini Caterina , Jenkins Robert B. , Parney Ian F. , Sarkaria Jann N.
Published: April 2023

Histologic diagnoses for all tumors implanted (WHO grade II-IV)
Supplementary Materials from Genomic and Phenotypic Characterization of a Broad Panel of Patient-Derived Xenografts Reflects the Diversity of Glioblastoma
Authors: Vaubel Rachael A. , Tian Shulan , Remonde Dioval , Schroeder Mark A. , Mladek Ann C. , Kitange Gaspar J. , Caron Alissa , Kollmeyer Thomas M. , Grove Rebecca , Peng Sen , Carlson Brett L. , Ma Daniel J. , Sarkar Gobinda , Evers Lisa , Decker Paul A. , Yan Huihuang , Dhruv Harshil D. , Berens Michael E. , Wang Qianghu , Marin Bianca M. , Klee Eric W. , Califano Andrea , LaChance Daniel H. , Eckel-Passow Jeanette E. , Verhaak Roel G. , Sulman Erik P. , Burns Terry C. , Meyer Fredrick B. , O'Neill Brian P. , Tran Nhan L. , Giannini Caterina , Jenkins Robert B. , Parney Ian F. , Sarkaria Jann N.
Published: April 2023

Figures S1-S8, Supplementary Methods, Supplementary Bibliography
Figure S1 from A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3
Authors: Choi Youn Jin , Hur Soo Young , Kim Tae-Jin , Hong Sung Ran , Lee Jae Kwan , Cho Chi-Heum , Park Ki Seok , Woo Jung Won , Sung Young Chul , Suh You Suk , Park Jong Sup
Published: April 2023

Figure S1 Clinical efficacy according at V7 and V8.
Supplementary Legend from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Authors: Fernández-Nogueira Patricia , Mancino Mario , Fuster Gemma , López-Plana Anna , Jauregui Patricia , Almendro Vanesa , Enreig Estel , Menéndez Silvia , Rojo Federico , Noguera-Castells Aleix , Bill Anke , Gaither L. Alex , Serrano Laia , Recalde-Percaz Leire , Moragas Núria , Alonso Raul , Ametller Elisabet , Rovira Ana , Lluch Ana , Albanell Joan , Gascon Pere , Bragado Paloma
Published: April 2023

Supplementary Legend
eTable3 from Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy
Authors: Sjöström Martin , Chang S. Laura , Fishbane Nick , Davicioni Elai , Hartman Linda , Holmberg Erik , Feng Felix Y. , Speers Corey W. , Pierce Lori J. , Malmström Per , Fernö Mårten , Karlsson Per
Published: April 2023

Kappa values for signature agreement
Supplementary Figure S4 from Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation
Authors: Fernández-Nogueira Patricia , Mancino Mario , Fuster Gemma , López-Plana Anna , Jauregui Patricia , Almendro Vanesa , Enreig Estel , Menéndez Silvia , Rojo Federico , Noguera-Castells Aleix , Bill Anke , Gaither L. Alex , Serrano Laia , Recalde-Percaz Leire , Moragas Núria , Alonso Raul , Ametller Elisabet , Rovira Ana , Lluch Ana , Albanell Joan , Gascon Pere , Bragado Paloma
Published: April 2023

Characterization of HER2 transactivation by FGFR2 in HER2 targeted therapies resistant cell lines
Supplementary Table 2 from Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival
Authors: Tang Wei , Putluri Vasanta , Ambati Chandrashekar R. , Dorsey Tiffany H. , Putluri Nagireddy , Ambs Stefan
Published: April 2023

Differently expressed genes between GCDC-high vs. GCDC-low breast tumors
Supplemental Figure S3 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Authors: Rotow Julia K. , Gui Philippe , Wu Wei , Raymond Victoria M. , Lanman Richard B. , Kaye Frederic J. , Peled Nir , Fece de la Cruz Ferran , Nadres Brandon , Corcoran Ryan B. , Yeh Iwei , Bastian Boris C. , Starostik Petr , Newsom Kimberly , Olivas Victor R. , Wolff Alexander M. , Fraser James S. , Collisson Eric A. , McCoach Caroline E. , Camidge D. Ross , Pacheco Jose , Bazhenova Lyudmila , Li Tianhong , Bivona Trever G. , Blakely Collin M.
Published: April 2023

MET tyrosine kinase domain modeling location of the F1200 residue
Supplemental Figure S2 from Co-occurring Alterations in the RAS–MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer
Authors: Rotow Julia K. , Gui Philippe , Wu Wei , Raymond Victoria M. , Lanman Richard B. , Kaye Frederic J. , Peled Nir , Fece de la Cruz Ferran , Nadres Brandon , Corcoran Ryan B. , Yeh Iwei , Bastian Boris C. , Starostik Petr , Newsom Kimberly , Olivas Victor R. , Wolff Alexander M. , Fraser James S. , Collisson Eric A. , McCoach Caroline E. , Camidge D. Ross , Pacheco Jose , Bazhenova Lyudmila , Li Tianhong , Bivona Trever G. , Blakely Collin M.
Published: April 2023

Summary of mutation clonality across patient cohorts
Supplementary Table 4 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Authors: Wasserman Isaac , Lee Lik Hang , Ogino Shuji , Marco Michael R. , Wu Chao , Chen Xi , Datta Jashodeep , Sadot Eran , Szeglin Bryan , Guillem Jose G. , Paty Philip B. , Weiser Martin R. , Nash Garrett M. , Saltz Leonard , Barlas Afsar , Manova-Todorova Katia , Uppada Srijaya Prakash Babu , Elghouayel Arthur E. , Ntiamoah Peter , Glickman Jonathan N. , Hamada Tsuyoshi , Kosumi Keisuke , Inamura Kentaro , Chan Andrew T. , Nishihara Reiko , Cercek Andrea , Ganesh Karuna , Kemeny Nancy E. , Dhawan Punita , Yaeger Rona , Sawyers Charles L. , Garcia-Aguilar Julio , Giannakis Marios , Shia Jinru , Smith J. Joshua
Published: April 2023

Ordinal logistic regression analyses to assess the association of SMAD4 expression status with lymphocytic reaction patterns in validation cohort
Supplementary Table 3 from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Authors: Wasserman Isaac , Lee Lik Hang , Ogino Shuji , Marco Michael R. , Wu Chao , Chen Xi , Datta Jashodeep , Sadot Eran , Szeglin Bryan , Guillem Jose G. , Paty Philip B. , Weiser Martin R. , Nash Garrett M. , Saltz Leonard , Barlas Afsar , Manova-Todorova Katia , Uppada Srijaya Prakash Babu , Elghouayel Arthur E. , Ntiamoah Peter , Glickman Jonathan N. , Hamada Tsuyoshi , Kosumi Keisuke , Inamura Kentaro , Chan Andrew T. , Nishihara Reiko , Cercek Andrea , Ganesh Karuna , Kemeny Nancy E. , Dhawan Punita , Yaeger Rona , Sawyers Charles L. , Garcia-Aguilar Julio , Giannakis Marios , Shia Jinru , Smith J. Joshua
Published: April 2023

Distribution of colorectal cancer cases according to SMAD4 expression status and immune response to the tumor in validation cohort
Supplementary Figure Legends from SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance
Authors: Wasserman Isaac , Lee Lik Hang , Ogino Shuji , Marco Michael R. , Wu Chao , Chen Xi , Datta Jashodeep , Sadot Eran , Szeglin Bryan , Guillem Jose G. , Paty Philip B. , Weiser Martin R. , Nash Garrett M. , Saltz Leonard , Barlas Afsar , Manova-Todorova Katia , Uppada Srijaya Prakash Babu , Elghouayel Arthur E. , Ntiamoah Peter , Glickman Jonathan N. , Hamada Tsuyoshi , Kosumi Keisuke , Inamura Kentaro , Chan Andrew T. , Nishihara Reiko , Cercek Andrea , Ganesh Karuna , Kemeny Nancy E. , Dhawan Punita , Yaeger Rona , Sawyers Charles L. , Garcia-Aguilar Julio , Giannakis Marios , Shia Jinru , Smith J. Joshua
Published: April 2023

Supplementary Figures 1 - 3
Supplementary Data from Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Authors: Kim Haesook T. , Ahn Kwang Woo , Hu Zhen-Huan , Davids Matthew S. , Volpe Virginia O. , Antin Joseph H. , Sorror Mohamed L. , Shadman Mazyar , Press Oliver , Pidala Joseph , Hogan William , Negrin Robert , Devine Steven , Uberti Joseph , Agura Edward , Nash Richard , Mehta Jayesh , McGuirk Joseph , Forman Stephen , Langston Amelia , Giralt Sergio A. , Perales Miguel-Angel , Battiwalla Minoo , Hale Gregory A. , Gale Robert Peter , Marks David I. , Hamadani Mehdi , Ganguly Sid , Bacher Ulrike , Lazarus Hillard , Reshef Ran , Hildebrandt Gerhard C. , Inamoto Yoshihiro , Cahn Jean-Yves , Solh Melhem , Kharfan-Dabaja Mohamed A. , Ghosh Nilanjan , Saad Ayman , Aljurf Mahmoud , Schouten Harry C. , Hill Brian T. , Pawarode Attaphol , Kindwall-Keller Tamila , Saba Nakhle , Copelan Edward A. , Nathan Sunita , Beitinjaneh Amer , Savani Bipin N. , Cerny Jan , Grunwald Michael R. , Yared Jean , Wirk Baldeep M. , Nishihori Taiga , Chhabra Saurabh , Olsson Richard F. , Bashey Asad , Gergis Usama , Popat Uday , Sobecks Ronald , Alyea Edwin , Saber Wael , Brown Jennifer R.
Published: April 2023

Supplementary Material
Supplementary Table S6 from Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8–CXCR2 Axis
Authors: Ogawa Ryotaro , Yamamoto Takamasa , Hirai Hideyo , Hanada Keita , Kiyasu Yoshiyuki , Nishikawa Gen , Mizuno Rei , Inamoto Susumu , Itatani Yoshiro , Sakai Yoshiharu , Kawada Kenji
Published: April 2023

Tumor characteristics. Preoperative serum samples from another cohort of 125 patients.
Supplementary Table 2 from Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste
Authors: Smith Stuart J. , Tyler Betty M. , Gould Toby , Veal Gareth J. , Gorelick Noah , Rowlinson Jonathan , Serra Riccardo , Ritchie Alison , Berry Phillip , Otto Annette , Choi John , Skuli Nicolas , Estevez-Cebrero Maria , Shakesheff Kevin M. , Brem Henry , Grundy Richard G. , Rahman Ruman
Published: April 2023

Supplementary Table
Supplementary Table 1 from Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste
Authors: Smith Stuart J. , Tyler Betty M. , Gould Toby , Veal Gareth J. , Gorelick Noah , Rowlinson Jonathan , Serra Riccardo , Ritchie Alison , Berry Phillip , Otto Annette , Choi John , Skuli Nicolas , Estevez-Cebrero Maria , Shakesheff Kevin M. , Brem Henry , Grundy Richard G. , Rahman Ruman
Published: April 2023

Supplementary Table
Supplementary Figure 4 from Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste
Authors: Smith Stuart J. , Tyler Betty M. , Gould Toby , Veal Gareth J. , Gorelick Noah , Rowlinson Jonathan , Serra Riccardo , Ritchie Alison , Berry Phillip , Otto Annette , Choi John , Skuli Nicolas , Estevez-Cebrero Maria , Shakesheff Kevin M. , Brem Henry , Grundy Richard G. , Rahman Ruman
Published: April 2023

Supplementary Figure 4 and Legend
Supplementary Figure 3 from Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste
Authors: Smith Stuart J. , Tyler Betty M. , Gould Toby , Veal Gareth J. , Gorelick Noah , Rowlinson Jonathan , Serra Riccardo , Ritchie Alison , Berry Phillip , Otto Annette , Choi John , Skuli Nicolas , Estevez-Cebrero Maria , Shakesheff Kevin M. , Brem Henry , Grundy Richard G. , Rahman Ruman
Published: April 2023

Supplementary Figure 3 and Legend
Supplementary Table S1 from Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8–CXCR2 Axis
Authors: Ogawa Ryotaro , Yamamoto Takamasa , Hirai Hideyo , Hanada Keita , Kiyasu Yoshiyuki , Nishikawa Gen , Mizuno Rei , Inamoto Susumu , Itatani Yoshiro , Sakai Yoshiharu , Kawada Kenji
Published: April 2023

List of antibodies used for IHC, IF and western blotting.
Supplementary Data from Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste
Authors: Smith Stuart J. , Tyler Betty M. , Gould Toby , Veal Gareth J. , Gorelick Noah , Rowlinson Jonathan , Serra Riccardo , Ritchie Alison , Berry Phillip , Otto Annette , Choi John , Skuli Nicolas , Estevez-Cebrero Maria , Shakesheff Kevin M. , Brem Henry , Grundy Richard G. , Rahman Ruman
Published: April 2023

Supplementary Figures and Tables
Supplementary Data from Loss of SMAD4 Promotes Colorectal Cancer Progression by Recruiting Tumor-Associated Neutrophils via the CXCL1/8–CXCR2 Axis
Authors: Ogawa Ryotaro , Yamamoto Takamasa , Hirai Hideyo , Hanada Keita , Kiyasu Yoshiyuki , Nishikawa Gen , Mizuno Rei , Inamoto Susumu , Itatani Yoshiro , Sakai Yoshiharu , Kawada Kenji
Published: April 2023

Supplementary Figure legend
Supplementary Data from Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste
Authors: Smith Stuart J. , Tyler Betty M. , Gould Toby , Veal Gareth J. , Gorelick Noah , Rowlinson Jonathan , Serra Riccardo , Ritchie Alison , Berry Phillip , Otto Annette , Choi John , Skuli Nicolas , Estevez-Cebrero Maria , Shakesheff Kevin M. , Brem Henry , Grundy Richard G. , Rahman Ruman
Published: April 2023

Supplementary Methods
Supplementary Figure S3 from Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer
Authors: Hurvitz Sara A. , Martin Miguel , Press Michael F. , Chan David , Fernandez-Abad María , Petru Edgar , Rostorfer Regan , Guarneri Valentina , Huang Chiun-Sheng , Barriga Susana , Wijayawardana Sameera , Brahmachary Manisha , Ebert Philip J. , Hossain Anwar , Liu Jiangang , Abel Adam , Aggarwal Amit , Jansen Valerie M. , Slamon Dennis J.
Published: April 2023

A. Subgroup analyses of percent change in Ki67 from baseline to week 2 were performed on KE population based on progesterone receptor status, tumor size, baseline disease stage, tumor grade, baseline lymph node involvement, and baseline Ki67 (index 20%). B. Ki67 changes at baseline, 2 weeks, and end of treatment. C. Geometric mean percentage suppression of Ki67 from baseline to end of treatment by treatment arm. D. Mean percentage rate of response as determined by complete cell cycle arrest (responder: Ki76<2.7) at end of treatment, by treatment arm. E. Effect of study treatment discontinuation on cell proliferation. F. Tissue expression of Ki67 from representative patients who were on treatment or off treatment for more than 4 days.
Table S4 from Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability
Authors: Murga-Zamalloa Carlos , Rolland Delphine C.M. , Polk Avery , Wolfe Ashley , Dewar Hiran , Chowdhury Pinki , Onder Ozlem , Dewar Rajan , Brown Noah A. , Bailey Nathanael G. , Inamdar Kedar , Lim Megan S. , Elenitoba-Johnson Kojo S.J. , Wilcox Ryan A.
Published: April 2023

Detailed list of signaling pathways identified by KEGG software.
Table S3 from Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability
Authors: Murga-Zamalloa Carlos , Rolland Delphine C.M. , Polk Avery , Wolfe Ashley , Dewar Hiran , Chowdhury Pinki , Onder Ozlem , Dewar Rajan , Brown Noah A. , Bailey Nathanael G. , Inamdar Kedar , Lim Megan S. , Elenitoba-Johnson Kojo S.J. , Wilcox Ryan A.
Published: April 2023

Phosphopeptides detected by mass-spectrometry screening in Karpas 299 lines with significant changes in phosphorylation upon treatment with pexidartinib (p<0.05).
Figure S3 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
Authors: Boeri Mattia , Milione Massimo , Proto Claudia , Signorelli Diego , Lo Russo Giuseppe , Galeone Carlotta , Verri Carla , Mensah Mavis , Centonze Giovanni , Martinetti Antonia , Sottotetti Elisa , Pastorino Ugo , Garassino Marina Chiara , Sozzi Gabriella
Published: April 2023

Figure S3 shows the trend of the MSC risk level in course of treatment with ICIs
Table S1 from Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability
Authors: Murga-Zamalloa Carlos , Rolland Delphine C.M. , Polk Avery , Wolfe Ashley , Dewar Hiran , Chowdhury Pinki , Onder Ozlem , Dewar Rajan , Brown Noah A. , Bailey Nathanael G. , Inamdar Kedar , Lim Megan S. , Elenitoba-Johnson Kojo S.J. , Wilcox Ryan A.
Published: April 2023

Phosphopeptides detected by mass spectrometry screening in Karpas 299 lines (phosphotyrosine enrichment) after treatment with DMSO or pexidartinib.
Figure S1 from Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
Authors: Boeri Mattia , Milione Massimo , Proto Claudia , Signorelli Diego , Lo Russo Giuseppe , Galeone Carlotta , Verri Carla , Mensah Mavis , Centonze Giovanni , Martinetti Antonia , Sottotetti Elisa , Pastorino Ugo , Garassino Marina Chiara , Sozzi Gabriella
Published: April 2023

Figure S1 reports PFS and OS of the whole series
Figure S5 from Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability
Authors: Murga-Zamalloa Carlos , Rolland Delphine C.M. , Polk Avery , Wolfe Ashley , Dewar Hiran , Chowdhury Pinki , Onder Ozlem , Dewar Rajan , Brown Noah A. , Bailey Nathanael G. , Inamdar Kedar , Lim Megan S. , Elenitoba-Johnson Kojo S.J. , Wilcox Ryan A.
Published: April 2023

Phosphoproteomic screening downstream of CSF1R inhibition.
Supplementary Figures from TAp73 Modifies Metabolism and Positively Regulates Growth of Cancer Stem–Like Cells in a Redox-Sensitive Manner
Authors: Sharif Tanveer , Dai Cathleen , Martell Emma , Ghassemi-Rad Mohammad Saleh , Hanes Mark Robert , Murphy Patrick J. , Kennedy Barry E. , Venugopal Chitra , Subapanditha Minomi , Giacomantonio Carman A. , Marcato Paola , Singh Sheila K. , Gujar Shashi
Published: April 2023

Supplementary Figures
Supplementary Figures from Fucosylation Enhances the Efficacy of Adoptively Transferred Antigen-Specific Cytotoxic T Lymphocytes
Authors: Alatrash Gheath , Qiao Na , Zhang Mao , Zope Madhushree , Perakis Alexander A. , Sukhumalchandra Pariya , Philips Anne V. , Garber Haven R. , Kerros Celine , St. John Lisa S. , Khouri Maria R. , Khong Hiep , Clise-Dwyer Karen , Miller Leonard P. , Wolpe Steve , Overwijk Willem W. , Molldrem Jeffrey J. , Ma Qing , Shpall Elizabeth J. , Mittendorf Elizabeth A.
Published: April 2023

Supplementary Figures
Supplementary Data from Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma
Authors: Azmi Asfar S. , Khan Husain Yar , Muqbil Irfana , Aboukameel Amro , Neggers Jasper E. , Daelemans Dirk , Mahipal Amit , Dyson Gregory , Kamgar Mandana , Al-Hallak Mohammad Najeeb , Tesfaye Anteneh , Kim Steve , Shidham Vinod , M. Mohammad Ramzi , Philip Philip A.
Published: April 2023

Supplementary figures
Supplementary Figure Legends from Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade
Authors: House Imran G. , Savas Peter , Lai Junyun , Chen Amanda X.Y. , Oliver Amanda J. , Teo Zhi L. , Todd Kirsten L. , Henderson Melissa A. , Giuffrida Lauren , Petley Emma V. , Sek Kevin , Mardiana Sherly , Gide Tuba N. , Quek Camelia , Scolyer Richard A. , Long Georgina V. , Wilmott James S. , Loi Sherene , Darcy Phillip K. , Beavis Paul A.
Published: April 2023

Supplementary Figure Legends
Table S6 from Genetic Ancestry–dependent Differences in Breast Cancer–induced Field Defects in the Tumor-adjacent Normal Breast
Authors: Nakshatri Harikrishna , Kumar Brijesh , Burney Heather N. , Cox Mary L. , Jacobsen Max , Sandusky George E. , D'Souza-Schorey Crislyn , Storniolo Anna Maria V.
Published: April 2023

Differences in Staining of NAT among European Ancestry versus African Americans
Supplementary Table S4 from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Authors: Kwon Minsuk , Kim Chang Gon , Lee Hoyoung , Cho Hyunsoo , Kim Youngun , Lee Eung Chang , Choi Seong Jin , Park Junsik , Seo In-Ho , Bogen Bjarne , Song Ik-Chan , Jo Deog-Yeon , Kim Jin Seok , Park Su-Hyung , Choi Inhak , Choi Yoon Seok , Shin Eui-Cheol
Published: April 2023

Supplementary Table S4
Supplementary Figure 1 from Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer
Authors: Gerber David E. , Infante Jeffrey R. , Gordon Michael S. , Goldberg Sarah B. , Martín Miguel , Felip Enriqueta , Martinez Garcia Maria , Schiller Joan H. , Spigel David R. , Cordova Julie , Westcott Valerie , Wang Yulei , Shames David S. , Choi YounJeong , Kahn Robert , Dere Randall C. , Samineni Divya , Xu Jian , Lin Kedan , Wood Katie , Royer-Joo Stephanie , Lemahieu Vanessa , Schuth Eva , Vaze Anjali , Maslyar Daniel , Humke Eric W. , Burris Howard A.
Published: April 2023

Supplementary Figure S1. CA125 response to lifastuzumab vedotin in ovarian cancer patients. All patients with radiographic responses also had {greater than or equal to}50 decrease in CA125 from baseline levels.
Supplementary Figures S1-S21 from PD-1 Blockade Reinvigorates Bone Marrow CD8+ T Cells from Patients with Multiple Myeloma in the Presence of TGFβ Inhibitors
Authors: Kwon Minsuk , Kim Chang Gon , Lee Hoyoung , Cho Hyunsoo , Kim Youngun , Lee Eung Chang , Choi Seong Jin , Park Junsik , Seo In-Ho , Bogen Bjarne , Song Ik-Chan , Jo Deog-Yeon , Kim Jin Seok , Park Su-Hyung , Choi Inhak , Choi Yoon Seok , Shin Eui-Cheol
Published: April 2023

Supplementary Figures S1-S21
Table S4 from Metformin Abrogates Age-Associated Ovarian Fibrosis
Authors: McCloskey Curtis W. , Cook David P. , Kelly Brendan S. , Azzi Feryel , Allen Christian H. , Forsyth Amanda , Upham Jeremy , Rayner Katey J. , Gray Douglas A. , Boyd Robert W. , Murugkar Sangeeta , Lo Bryan , Trudel Dominique , Senterman Mary K. , Vanderhyden Barbara C.
Published: April 2023

Gene annotations used to generate cell type scores